REGULATORY

• Orphan Status Withdrawn for 4 Flu Vaccines: MHLW Notification
  March 13, 2017

• MHLW to Stockpile Enough Avigan for 30,000 Persons
  March 13, 2017

• Drug Prices Should Be Raised for Products with Good Outcomes: Shiozaki
  March 10, 2017

• Change Necessary for Ethical Drug Distribution Rules, Shiozaki Says after Fake Harvoni Fuss
  March 10, 2017

• Reference Pricing on Agenda for CEFP Social Security Working Group
  March 10, 2017

• NIBIOHN Looks to Spur Next-Gen Drug Development with Unique Antibody Techs, Joins Hands with 10 Companies
  March 9, 2017

• MHLW to Set Up Panel on Drug Distribution after Fake Harvoni Flub, Eyes GDP Ordinance
  March 8, 2017

• MHLW’s Guide to Recommend Against Prescribing Antibacterials for Colds, Diarrhea
  March 8, 2017

• Tap Real-World Data for Optimal Use of High-Priced Meds: MHLW Bureau Chief
  March 7, 2017

• 3 Kansai Medico Pharmacies Slapped with Biz Improvement Order over Fake Harvoni
  March 7, 2017

• MHLW to Update Its Generic Roadmap in Line with Govt Target: Official
  March 7, 2017

• PMDA Certified as APEC’s Training Center of Excellence for Regulatory Science
  March 6, 2017

• Official Raw Plasma Prices for FY2017 Virtually Flat: MHLW Panel
  March 6, 2017

• Panel OKs Orphan Designations for Olaparib, Inotuzumab Ozogamicin
  March 6, 2017

• Opdivo Approval for Head and Neck Cancer Expected in Late March-Early April
  March 6, 2017

• MHLW Advisory Committee OKs Ninlaro, Sovaldi for Genotypes 3-6
  March 6, 2017

• MHLW OKs Add’l Indications for Revlimid, Other Drugs
  March 3, 2017

• Orphan Status Dropped for 3 Drugs, Designation Given to Canakinumab
  March 3, 2017

• Industry Reps Call for Early Discussions on Inclusion of Vaccines in Public Vaccination Programs: Hearings
  March 3, 2017

• MHLW Advisory Panel Backs Shionogi’s Pediatric ADHD Drug
  March 3, 2017

ページ

• « 先頭
• ‹ Prev
• …
• 251
• 252
• 253
• 254
• 255
• 256
• 257
• 258
• 259
• …
• Next ›
• 最終 »